改善心力衰竭随机对照临床试验区域代表性的策略
Guillaume Baudry1, Luca Monzo1, Rebecca A V Newton2
1Université de Lorraine, INSERM, Centre d'Investigation Clinique Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, REICATRA, Nancy, France.
Nature cardiovascular research
|March 5, 2026
概括
对心血管疾病 (如心力衰竭) 的临床试验缺乏全球多样性,主要招募来自北美和欧洲的参与者. 提高试验代表性对于全球健康公平和准确的研究结果至关重要.
科学领域:
- 心血管研究的心血管研究.
- 临床试验方法论 临床试验方法论
- 卫生公平性健康公平性
背景情况:
- 在心血管疾病中,关键随机对照试验 (RCT) 从历史上来看过度代表北美和欧洲.
- 这种区域偏差限制了试验结果的概括性和外部有效性.
- 心力衰竭试验是检查这些代表性差距的案例研究.
研究的目的:
- 审查区域参与心血管RCT的演变情况.
- 确定试验代表性的现有差距,并提出解决方案.
- 解决阻碍代表性不足地区入学的障碍.
主要方法:
- 分析了40年来心血管RCT的区域招生趋势.
- 评估参与试验的监管,后勤和财务障碍.
- 审查当前的区域分类系统,并提出标准化建议.
主要成果:
- 实验室实验室的招生集中在北美和欧洲,无法反映全球疾病分布.
- 在代表性不足的地区,临床试验招生存在重大障碍.
- 建议制定一个标准化的区域分类系统和代表性指数.
结论:
- 提高RCT的区域代表性对于提高试验效率和外部有效性至关重要.
- 需要针对解决多层次障碍的有针对性的战略,以增加代表性不足的地区的参与.
- 在全球范围内扩大试验招生促进健康公平和更强有力的科学证据.
更多相关视频
相关概念视频
Heart Failure V: Medical Management
441
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
441
Heart Failure VI: Adjunct Therapies
488
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
488
Heart Failure IV: Classification and Diagnostic Evaluation
503
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
503
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure VII: Nursing Interventions
613
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
613
Heart Failure Drugs: β-Blockers
1.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.0K


